September 15, 2025

Dana-Farber Research News 09.15.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 16 - August 31.

Dana-Farber

September 15, 2025

Pilot study tests ALS drug to treat chemo brain in cancer patients

A first-of-its-kind study tests ALS drug riluzole to restore cognitive function in cancer survivors.

UCI Health

September 11, 2025

Revumenib in Triplet Regimen Under Study in Newly Diagnosed AML With NPM1/KMT2A Alterations

A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid leukemia and an NPM1 m...

The ASCO Post

September 11, 2025

Treatment of Anal Precancer May Lower Cancer Risk in HIV

Routine screening now includes anoscopy to confirm positive anal Pap or HPV test results.

Conexiant

September 05, 2025

Can GLP-1s Double Colorectal Cancer Risk?

More than 5 million patients were included across seven retrospective studies.

Conexiant

September 02, 2025

Implementation of an Electronic Health Record Alert to Improve Naloxone Coprescribing for Adult Patients With Cancer at Risk for Opioid Overdose

A quality improvement initiative has transformed naloxone coprescribing practices for cancer patients at risk of opioid overdose, addressing key safety concerns in opioid management (source: Ruano et al., 2022).

JADPRO

September 02, 2025

Misconceptions Regarding Skin Cancer Risk in the United States

Investigators may have uncovered associations between the reported number of sunburns and sociodemographic characteristics as well as the prevalence of protective skin behaviors adopted by U.S. adults...

The ASCO Post

September 02, 2025

Can ctDNA Monitoring Help to Predict Melanoma Recurrence?

A new report shows how droplet digital polymerase chain reaction assays focusing on monitoring the most common mutations in the genetic code in melanoma cells—BRAF V600E and BRAF V600K—may help to pre...

The ASCO Post

September 02, 2025

Use of Niraparib in Patients With Advanced Melanoma

Researchers are exploring the early outcomes with niraparib in patients with advanced melanoma whose tumors have specific genetic changes impacting DNA repair.

The ASCO Post